n n n ‘. concat(e. i18n. t(“search. voice. recognition_retry”),’n
MADRID (Reuters) – Spanish pharmaceutical company Rovi said on Thursday it had hired asset control and money advisory firm Lazard to explore the sale of its third-party production business that it uses to make COVID vaccines.
Madrid-based Rovi said it is evaluating potential strategic opportunities to maximize the price and has made a resolution to lease Lazard, though no express resolution has been reached and the investigation is still ongoing.
The third-party production business, which includes a long-term partnership with Moderna to manufacture its COVID-19 vaccine for large parts of the world, accounted for nearly a share of Rovi’s 2023 profits of about 830 million euros ($904 million).
Rovi shares were up 4% in early trading on Thursday. Its shares are up 30% year-to-date, bringing the company’s market capitalization to €4 billion.
($1 = €0. 9179)
(Reporting by Emma Pinedo, editing by Andrei Khalip and David Evans)